Journal

Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent

Read time: 1 mins

Published:31st Aug 2021

Author: Rastogi A, Hanna RM, Mkrttchyan A, Khalid M, Yaqoob S, Shaffer K et al.

Source: Expert Review of Clinical Pharmacology

Availability: Pay for access, or by subscription

Ref.:Expert Rev Clin Pharmacol. 2021 Sep;14(9):1055-1064.

DOI:10.1080/17512433.2021.1932460

Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent

Introduction: Hyperkalemia is a common finding in patients with advanced kidney disease for multiple reasons. Renin-Angiotensin-Aldosterone-System Inhibitors (RAASi) that are indicated for slowing down progression of kidney disease are often associated with hyperkalemia which becomes a limiting factor in their use and titration to the maximum dose. Having a safe, effective, tolerable, and affordable potassium binder can help optimize RAAS inhibition in the setting of kidney disease.

Areas covered: Although sodium polystyrene sulfonate has been a mainstay of acute management of hyperkalemia for decades, evidence regarding its efficacy is limited, and its chronic use is not routinely recommended for concerns regarding toxicity. The concern of gastrointestinal (GI) adverse effects with sodium polystyrene sulfonate has spurred the development of alternatives. Sodium zirconium cyclosilicate (SZC) is a promising agent that selectively binds potassium in the gut and eliminates it, while being safe for chronic use based on 1 year of data. Even though we do not have head-to-head studies among the three currently available binders, SZC stands out in rapidity of onset and efficacy.

Expert opinion: In this review, we summarize the general management of hyperkalemia, including new agents. We review the pre-clinical and clinical data relating to sodium zirconium cyclosilicate.

Read abstract on library site Access full article

Hyperkalaemia

Containing relevant Learning Zones, guidelines, trials and news.

Chronic Kidney Disease

Containing relevant Learning Zones, guidelines, trials and news.

Glomerulonephritis

Containing relevant Learning Zones, guidelines, trials and news.

Featured Learning Zones

patient receiving dialysis, hospital image

Learning Zone Homepage

Chronic Kidney Disease Learning Zone

Chronic Kidney Disease (CKD) is a disease that can often lead to a need for haemodialysis and kidney transplantation. New CKD treatments are emerging which focus on delaying CKD disease progression and the need for transplantation.

You may be interested in...

Guideline

The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline

This BSH guideline summarises the recommended initial investigation and first-line management of large B-cell lymphoma (LBCL).

Guideline

Canadian Evidence-Based Guideline for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A group of experts from across Canada have developed a national evidence-based treatment guideline to provide healthcare professionals with clear guidance on the management of relapsed or refractory DLBCL. Results of the current provincial guidelines in existence are presented with consensus recommendations based on available evidence.

Guideline

Canadian Evidence-Based Guideline For The Frontline Treatment of Diffuse Large B-Cell Lymphoma

A group of experts from across Canada developed a national evidence-based treatment guideline to provide healthcare professionals with clear guideline and best practices for the management of frontline DLBCL. Results of the current provincial guidelines in existence are presented with consensus recommendations based on available evidence.